Press Releases

Press Releases

Jun 07, 2023
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
Jun 06, 2023
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
Jun 02, 2023
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
May 22, 2023
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2023
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Apr 28, 2023
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
Apr 18, 2023
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
Mar 14, 2023
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
Feb 28, 2023
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 02, 2023
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Displaying 11 - 20 of 21
Media & IR Contact
Investor Contact

Robin Garner
Investor Relations
Contact Us

Media Contact

David Rosen
Argot Partners
[email protected]

Helpful Tools